Antibodies
Alfuzosin HCl is an alpha1 receptor antagonist used to treat benign prostatic hyperplasia (BPH).
| Size | Price | Stock | Quantity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Alfuzosin(Uroxatral) is an alpha1 receptor antagonist used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. [2]
| NCT Number | Recruitment | Conditions | Sponsor /Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01834729 | Recruiting | Constipation | Mayo Clinic | Phase 2 | |
| NCT01435954 | Completed | Benign Prostatic Hyperplasia | GlaxoSmithKline | ||
| NCT01332487 | Completed | Prostatic Hyperplasia | GlaxoSmithKline | ||
| NCT01323998 | Completed | Prostatic Hyperplasia | GlaxoSmithKline | ||
| NCT01332435 | Completed | Prostatic Hyperplasia | GlaxoSmithKline |
| Molecular Weight (MW) | 425.91 |
|---|---|
| Formula | C19H27N5O4.HCl |
| CAS No. | 81403-68-1 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | Uroxatral |
| Solubility (25°C) * | In vitro | DMSO | 85 mg/mL (199 mM) |
|---|---|---|---|
| Water | 85 mg/mL (199 mM) | ||
| Ethanol | 85 mg/mL (199 mM) | ||
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name | N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)propyl)-tetrahydrofuran-2-carboxamide |
|---|
| Stock Solution (1ml DMSO) | 1mM | 10mM | 20mM | 30mM |
|---|---|---|---|---|
| Mass(mg) | 0.42591 | 4.2591 | 8.5182 | 12.7773 |